Drug Trial Radar · NCT06926842
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Apr 22, 2025
Primary completion
Aug 13, 2026
Study completion Aug 13, 2026
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Conditions
- Overweight
- Type 2 Diabetes
- Obesity
Interventions
PetrelintideDrug
Petrelintide will be taken by participants once weekly subcutaneously.
PlaceboOther
Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in Body WeightTime frame: From Baseline (Day 1) to Weeks 28
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Cullman Clinical Trials - Family Medicine
Cullman, Alabama
AZ Endocrine Institute
Chandler, Arizona
Elite Clinical Studies, LLC
Phoenix, Arizona
M3 Wake Research, Tucson Neuroscience Research, LLC
Tucson, Arizona
Medical Investigation Inc
Little Rock, Arkansas
Velocity Clinical Research
Huntington Park, California
Velocity Clinical Research, North Hollywood
North Hollywood, California
Exalt Clinical Research
San Diego, California
Diablo Clinical Research Inc.
Walnut Creek, California
Chase Medical Research, LLC
Waterbury, Connecticut
Emerson Clinical Research
Washington D.C., District of Columbia
Innovative Research of West Florida
Clearwater, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
Solutions Through Advanced Research, Inc
Jacksonville, Florida
M3 Wake Research - Lake City
Lake City, Florida
West Orange Endocrinology P.A
Ocoee, Florida
Palm Beach Research Center
West Palm Beach, Florida
M3 Wake Research - Atlanta
Atlanta, Georgia
East Coast Institute for Research - Canton
Canton, Georgia
Privia Medical Group Georgia, LLC
Savannah, Georgia
Great Lakes Clinical Trials
Chicago, Illinois
Iowa Diabetes & Endocrinology Research Center
West Des Moines, Iowa
Heartland Research Associates, LLC
Wichita, Kansas
DelRicht Research - New Orleans
New Orleans, Louisiana
AAMRC
Flint, Michigan
International Diabetes Center
Minneapolis, Minnesota
Velocity Clinical Research, Gulfport
Gulfport, Mississippi
AMR Kansas City
Kansas City, Missouri
Mercury Street Medical Group, PLLC
Butte, Montana
M3 Wake Research - Las Vegas, NV
Las Vegas, Nevada
Palm Research Center, Inc.
Las Vegas, Nevada
Javara Inc
Charlotte, North Carolina
PharmQuest Life Sciences, LLC
Greensboro, North Carolina
M3 Wake Research
Raleigh, North Carolina
Velocity Clinical Research, Cincinnati, Mt. Auburn
Cincinnati, Ohio
Centricity Research
Columbus, Ohio
Lynn Institute of Norman
Norman, Oklahoma
M3 Wake Research - Charleston
Charleston, South Carolina
M3 Wake Research/ClinSearch, LLC
Chattanooga, Tennessee
Elligo Clinical Research, Inc.
Austin, Texas
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.